(ALTS) ALT5 Sigma - Ratings and Ratios
Trading Platform, Payment Gateway, Sodium Nitrite Therapy, Low-Dose Naltrexone
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 120% |
| Value at Risk 5%th | 164% |
| Relative Tail Risk | -17.00% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.44 |
| Alpha | -92.23 |
| CAGR/Max DD | -0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.262 |
| Beta | 1.335 |
| Beta Downside | 1.148 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.69% |
| Mean DD | 44.15% |
| Median DD | 44.63% |
Description: ALTS ALT5 Sigma December 01, 2025
ALT5 Sigma Corporation (NASDAQ: ALTS) operates a dual-segment business model that combines blockchain-enabled fintech services with a biotechnology pipeline focused on non-opioid pain and addiction therapies.
In its Fintech segment, the firm offers ALT 5 Prime, an electronic over-the-counter platform for trading digital assets, and ALT 5 Pay, a crypto-payment gateway for merchants. The global crypto-asset market remains sizable-estimated at roughly $2.5 trillion in 2024-and transaction volumes have been growing at about 15 % year-over-year, creating a tailwind for settlement and payment solutions, while regulatory scrutiny in the U.S. and EU continues to evolve.
The Biotechnology segment pursues novel, non-addictive treatments. JAN 101, a sustained-release sodium nitrite formulation, has completed a Phase 2a trial for peripheral arterial disease and pain, and JAN 123 (low-dose naltrexone) targets chronic regional pain syndrome. The U.S. chronic pain market exceeds $100 billion annually, and FDA guidance released in early 2024 has signaled a more favorable pathway for non-opioid analgesics, potentially accelerating approval timelines.
Formerly JanOne Inc., the company rebranded to ALT5 Sigma in July 2024. Founded in 1976 and headquartered in Las Vegas, Nevada, ALTS remains a relatively small-cap entity (market-cap ≈ $120 million as of Q3 2024) with a cash runway projected to cover operations through mid-2025, assuming current burn rates.
If you’re looking for deeper quantitative analysis and comparable peer metrics, a quick look at ValueRay’s dashboard can help surface the data you need.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-16.7m TTM) > 0 and > 6% of Revenue (6% = 1.34m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -3.00pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -20.33% (prev -536.0%; Δ 515.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.05 (>3.0%) and CFO -4.49m > Net Income -16.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.6m) change vs 12m ago 120.7% (target <= -2.0% for YES) |
| Gross Margin 47.46% (prev 50.62%; Δ -3.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 26.17% (prev 2.88%; Δ 23.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.69 (EBITDA TTM -4.21m / Interest Expense TTM 2.15m) >= 6 (WARN >= 3) |
Altman Z'' -4.37
| (A) -0.05 = (Total Current Assets 33.7m - Total Current Liabilities 38.3m) / Total Assets 94.7m |
| (B) -0.73 = Retained Earnings (Balance) -68.9m / Total Assets 94.7m |
| (C) -0.09 = EBIT TTM -7.95m / Avg Total Assets 85.0m |
| (D) -1.01 = Book Value of Equity -65.9m / Total Liabilities 65.4m |
| Total Rating: -4.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.87
| 1. Piotroski 0.0pt |
| 2. FCF Yield -1.78% |
| 3. FCF Margin -20.16% |
| 4. Debt/Equity 0.87 |
| 5. Debt/Ebitda -3.12 |
| 6. ROIC - WACC (= -37.79)% |
| 7. RoE -74.91% |
| 8. Rev. Trend 92.28% |
| 9. EPS Trend -5.93% |
What is the price of ALTS shares?
Over the past week, the price has changed by -4.07%, over one month by -29.34%, over three months by -58.16% and over the past year by -74.68%.
Is ALTS a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALTS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | 1425.4% |
| Analysts Target Price | 18 | 1425.4% |
| ValueRay Target Price | 1.1 | -8.5% |
ALTS Fundamental Data Overview December 25, 2025
P/S = 6.5126
P/B = 16.6883
Beta = 1.6
Revenue TTM = 22.3m USD
EBIT TTM = -7.95m USD
EBITDA TTM = -4.21m USD
Long Term Debt = 17.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.36m USD (from shortTermDebt, last quarter)
Debt = 22.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.2m USD (from netDebt column, last quarter)
Enterprise Value = 251.8m USD (238.6m + Debt 22.7m - CCE 9.56m)
Interest Coverage Ratio = -3.69 (Ebit TTM -7.95m / Interest Expense TTM 2.15m)
FCF Yield = -1.78% (FCF TTM -4.49m / Enterprise Value 251.8m)
FCF Margin = -20.16% (FCF TTM -4.49m / Revenue TTM 22.3m)
Net Margin = -74.89% (Net Income TTM -16.7m / Revenue TTM 22.3m)
Gross Margin = 47.46% ((Revenue TTM 22.3m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = 43.51% (prev 46.99%)
Tobins Q-Ratio = 2.66 (Enterprise Value 251.8m / Total Assets 94.7m)
Interest Expense / Debt = 2.42% (Interest Expense 550.0k / Debt 22.7m)
Taxrate = 7.28% (-432.0k / -5.93m)
NOPAT = -7.37m (EBIT -7.95m * (1 - 7.28%)) [loss with tax shield]
Current Ratio = 0.88 (Total Current Assets 33.7m / Total Current Liabilities 38.3m)
Debt / Equity = 0.87 (Debt 22.7m / totalStockholderEquity, last quarter 26.1m)
Debt / EBITDA = -3.12 (negative EBITDA) (Net Debt 13.2m / EBITDA -4.21m)
Debt / FCF = -2.94 (negative FCF - burning cash) (Net Debt 13.2m / FCF TTM -4.49m)
Total Stockholder Equity = 22.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -17.60% (Net Income -16.7m / Total Assets 94.7m)
RoE = -74.91% (Net Income TTM -16.7m / Total Stockholder Equity 22.2m)
RoCE = -20.12% (EBIT -7.95m / Capital Employed (Equity 22.2m + L.T.Debt 17.3m))
RoIC = -27.61% (negative operating profit) (NOPAT -7.37m / Invested Capital 26.7m)
WACC = 10.18% (E(238.6m)/V(261.4m) * Re(10.94%) + D(22.7m)/V(261.4m) * Rd(2.42%) * (1-Tc(0.07)))
Discount Rate = 10.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 85.75%
Fair Price DCF = unknown (Cash Flow -4.49m)
EPS Correlation: -5.93 | EPS CAGR: 0.28% | SUE: N/A | # QB: 0
Revenue Correlation: 92.28 | Revenue CAGR: 451.4% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-0.60 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+41.8% | Growth Revenue=+66.9%
Additional Sources for ALTS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle